Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Income towards Parent Company: 2018-2022

Historic Income towards Parent Company for ADC Therapeutics (ADCT) over the last 5 years, with Dec 2022 value amounting to -$155,800.

  • ADC Therapeutics' Income towards Parent Company fell 189.52% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 216.62%. This contributed to the annual value of -$155,800 for FY2022, which is 32.27% up from last year.
  • ADC Therapeutics' Income towards Parent Company amounted to -$155,800 in FY2022, which was up 32.27% from -$230,026 recorded in FY2021.
  • ADC Therapeutics' 5-year Income towards Parent Company high stood at -$116,484 for FY2019, and its period low was -$246,290 during FY2020.
  • Over the past 3 years, ADC Therapeutics' median Income towards Parent Company value was -$230,026 (recorded in 2021), while the average stood at -$210,705.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 111.44% in 2020, then surged by 32.27% in 2022.
  • Yearly analysis of 5 years shows ADC Therapeutics' Income towards Parent Company stood at -$123,096 in 2018, then climbed by 5.37% to -$116,484 in 2019, then slumped by 111.44% to -$246,290 in 2020, then increased by 6.60% to -$230,026 in 2021, then surged by 32.27% to -$155,800 in 2022.